Larimar Therapeutics Inc (LRMR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Larimar Therapeutics Inc (LRMR) has a cash flow conversion efficiency ratio of -0.282x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-44.61 Million) by net assets ($158.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Larimar Therapeutics Inc to measure how much of total assets are equity-financed.
Larimar Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Larimar Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check LRMR cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Larimar Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Larimar Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Robo.ai Inc.
NASDAQ:AIIO
|
0.060x |
|
Beijing Bashi Media Co Ltd
SHG:600386
|
0.071x |
|
Metrodata Electronics Tbk
JK:MTDL
|
-0.162x |
|
Firma Oponiarska DĘBICA SA
WAR:DBC
|
0.069x |
|
Jacquet Metal Service SA
PA:JCQ
|
0.059x |
|
Five Point Holdings LLC
NYSE:FPH
|
-0.019x |
|
ENF Technology Co. Ltd
KQ:102710
|
0.071x |
|
LH Shopping Centers Leasehold
BK:LHSC
|
0.011x |
Annual Cash Flow Conversion Efficiency for Larimar Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Larimar Therapeutics Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Larimar Therapeutics Inc (LRMR) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $78.08 Million | $-113.20 Million | -1.450x | -252.00% |
| 2024-12-31 | $171.81 Million | $-70.76 Million | -0.412x | -0.59% |
| 2023-12-31 | $81.72 Million | $-33.46 Million | -0.409x | -64.71% |
| 2022-12-31 | $110.90 Million | $-27.57 Million | -0.249x | +61.97% |
| 2021-12-31 | $64.41 Million | $-42.10 Million | -0.654x | -38.94% |
| 2020-12-31 | $89.69 Million | $-42.20 Million | -0.470x | -101.44% |
| 2019-12-31 | $-694.00K | $-22.70 Million | 32.707x | +6025.11% |
| 2018-12-31 | $93.27 Million | $-51.49 Million | -0.552x | +1.39% |
| 2017-12-31 | $78.22 Million | $-43.78 Million | -0.560x | -31.10% |
| 2016-12-31 | $121.73 Million | $-51.98 Million | -0.427x | -21.25% |
| 2015-12-31 | $169.11 Million | $-59.55 Million | -0.352x | -30.24% |
| 2014-12-31 | $104.44 Million | $-28.24 Million | -0.270x | +36.52% |
| 2013-12-31 | $35.22 Million | $-15.00 Million | -0.426x | +74.75% |
| 2012-12-31 | $8.06 Million | $-13.59 Million | -1.687x | -- |
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.